Severe iMCD: Next-Line Management After Siltuximab and High-Dose Corticosteroid Failure

This protocol applies to patients with idiopathic multicentric Castleman disease (iMCD) who present with a severe, organ-threatening picture and have not responded adequately to initial targeted therapy — requiring prompt escalation to a more aggressive approach.

Clinical Scenario — Severe iMCD with Organ Dysfunction

Patients qualify when they meet at least 2 of the following 5 criteria:

ECOG performance status of 2 or greater
Stage IV renal dysfunction (eGFR below 30 or serum creatinine above 3.0 mg/dL)
Anasarca and/or ascites and/or pleural or pericardial effusion
Hemoglobin of 8.0 g/dL or lower
Pulmonary involvement or interstitial pneumonitis with dyspnea

Prior Treatment — Failure Condition

The preceding line — a high-dose corticosteroid regimen combined with siltuximab on an accelerated schedule (or tocilizumab with high-dose steroids when siltuximab was unavailable) — did not produce the required clear clinical and biochemical response within one week. Specifically: no meaningful improvement in CRP, hemoglobin, albumin, or GFR, or clinical deterioration at any point during daily assessment. Either of these failure signals triggers escalation to this protocol.

Next-Line Approach

Aggressive combination (multiagent) chemotherapy forms the basis of this step, directed at rapidly ablating the hyperactivated immune process driving the cytokine storm. The full structured regimen — including the specific options employed and the sequencing criteria — is available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood-2018-07-862334

Patients with severe iMCD have evidence of organ dysfunction such as renal failure, anasarca, severe anemia, and pulmonary dysfunction resulting in poor performance status likely requiring critical care.

Patients with severe iMCD must have at least 2 of the 5 criteria listed above.

Therefore, aggressive intervention with multiagent chemotherapy should be considered as early as necessary (any sign of deterioration or after 1 week of no response to siltuximab, whichever comes first) to ablate the hyperactivated immune system and stem the cytokine storm.

Chemotherapy regimens, including those for lymphoma: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone), or CVP (cyclophosphamide, vincristine, prednisone); myeloma: VDT-ACE-R (bortezomib, dexamethasone, thalidomide, doxorubicin, cyclophosphamide, etoposide, rituximab); or etoposide/cyclophosphamide-containing regimens as used for hemophagocytic lymphohistiocytosis have all been employed.

View source ↗